Show simple item record

dc.contributor.authorWei Zheng
dc.contributor.authorDong-Bin Cai
dc.contributor.authorWei Zheng
dc.contributor.authorKang Sim
dc.contributor.authorGabor S. Ungvari
dc.contributor.authorXiao-Jiang Peng
dc.contributor.authorYu-Ping Ning
dc.contributor.authorGang Wang
dc.contributor.authorYu-Tao Xiang
dc.date.accessioned2020-10-10T02:09:29Z
dc.date.available2020-10-10T02:09:29Z
dc.date.issued2019-09-08
dc.identifier.citationPsychiatry Research,2019,
dc.identifier.other10.1016/j.psychres.2019.07.006
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/174896
dc.description.abstractAbstract(#br)Objectives(#br)To systematically examine the effectiveness, tolerability, and safety of brexanolone infusion in treating postpartum depression (PPD).(#br)Methods(#br)Randomized controlled trials (RCTs) were included.(#br)Results(#br)Two articles reporting 3 RCTs with 4 active arms ( n = 267) covering 156 women with PPD receiving brexanolone infusion and 111 women with PPD on placebo were included. Compared with placebo, women suffering from PPD who received brexanolone had significantly greater response that started after 24 h (risk ratio (RR)=1.34, 95%CI 1.03–1.73), peaked at 36 h (RR = 1.50, 95%CI 1.06–2.13, P = 0.02) and lasted until Day 7 (RR = 1.32, 95%CI 1.01–1.73). Similarly, PPD women treated with brexanolone had significantly greater remission starting at 24 h (RR = 1.86, 95%CI 1.03–3.34), peaking at 60 h (RR = 2.20, 95%CI 1.31–3.70) and lasting until 72 h (RR = 1.96, 95%CI 1.41–2.72). Brexanolone infusion led to significantly higher rate of discontinuation for any reasons (RR = 2.68, 95%CI 1.35–5.32). Discontinuation due to intolerability and adverse drug reactions was similar between the active agent and placebo.(#br)Conclusion(#br)A single brexanolone infusion appears to have ultra-rapid antidepressant effect for PPD, lasting for up to 1 week. The short and long-term therapeutic effect of brexanolone needs to be examined in large-scale RCTs.
dc.language.isozh_CN
dc.subjectBrexanolone
dc.subjectPostpartum depression
dc.subjectMeta-analysis
dc.titleBrexanolone for postpartum depression: A meta-analysis of randomized controlled studies
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record